Background Real-life data on vedolizumab effectiveness in inflammatory bowel disease
(IBD) are still emerging. Data on the comparative safety of the gut selective profile are of …

Abstract Background and Aims Vedolizumab is a gut-selective antibody to α 4 β 7 integrin,
approved to treat moderate-to-severe ulcerative colitis and Crohn's disease in adults …

Background and aims: Vedolizumab inhibits leucocyte vascular adhesion and migration into
the gastrointestinal tract through α4β7 integrin blockade. This agent became available in …

Background Vedolizumab is now widely available for the treatment of moderate to severe
ulcerative colitis (UC) and Crohn's disease (CD). We sought to quantify the rates of …

Objective To gain an understanding of the efficacy of vedolizumab in a 'real-world'setting.
Design Retrospective cohort study using prospectively maintained clinical records. Setting …

Background Effectiveness of vedolizumab in real world clinical practice is unknown. Aim To
evaluate the short and long‐term effectiveness of vedolizumab in patients with inflammatory …

Background Vedolizumab is a gut‐selective antibody to α4β7 integrin approved to treat
moderate‐to‐severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel …

Background & Aims There are few real-world data on the safety of vedolizumab for treatment
of Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors …

Background Several studies have reported the surgical outcomes of inflammatory bowel
disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results …

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease
(IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We …